The first China shock was cheap plastic toys and textiles. The second was electronics, appliances and the slow hollowing-out of factory towns from Ohio to Emilia-Romagna. Now a growing chorus of economists says a third wave is forming, and this time the exports are not televisions or sneakers. They are robots, biologic drugs and software that thinks.
The phrase “China shock 3.0” has been circulating in trade and economics circles after a prominent economist used it to describe how Chinese advances in AI, biotechnology and robotics could hit developed economies through exports rather than domestic competition alone. The argument runs roughly like this: for two decades China competed on cost. In the next decade it will compete on capability, and that changes who gets hurt and how fast.
The manufacturing piece is the easiest to see coming. China already installs more industrial robots than the rest of the world combined, and its domestic robotics makers have spent years grinding down component costs. What used to be a market dominated by a handful of Japanese and European firms is now crowded with Chinese suppliers shipping everything from warehouse arms to autonomous mobile robots. When those companies turn outward, as Chinese firms in solar panels, batteries and EVs already have, the pricing pressure lands directly on Western automation vendors and the factories that buy from them.
Biotech is subtler but potentially more disruptive. Chinese drug developers have shifted from making generics to licensing novel compounds to global pharmaceutical companies, a reversal of the old model where Western firms sold into China. The volume of licensing deals has climbed sharply in recent years, and several Chinese-developed therapies have won overseas approvals. For an industry that depends on decade-long research pipelines, a new source of fast, cheaper innovation is both an opportunity and a threat. Western biotech investors now watch Chinese clinical trial data the way they once watched Silicon Valley startups.
Then there is AI, the wildcard. Chinese labs have released open-weight models that perform competitively on many benchmarks while costing a fraction of frontier systems to train and run. That matters less for chatbots and more for the unglamorous work of automating documents, code and customer service. If those models get embedded in Chinese export products, from phones to cars to medical devices, the intelligence becomes part of the good. You are no longer competing with a Chinese model. You are competing with a Chinese machine that has one inside.
Not everyone buys the alarm. Trade economists have long noted that predictions of Chinese dominance tend to overshoot. Export data is noisy, and much of China’s advanced manufacturing still depends on foreign chips, tools and software. Sanctions and export controls have complicated the picture, and Beijing’s own domestic slowdown has cooled some expansion plans. The word “shock” also implies suddenness, when the reality is usually a slow squeeze measured in quarterly market share rather than a single dramatic moment.
Still, the direction of travel is hard to argue with. Korea recently committed hundreds of billions of euros to build chips at home, a sign that even countries inside the supply chain are hedging. Europe’s push for its own fabs has run into cost and scale problems. The United States keeps tightening restrictions while trying to onshore production. Every one of these moves is a response to the same underlying concern: that the next industrial advantage will be built, not bought.
What makes this wave different from the first two is where the pain shows up. The first China shocks hit blue-collar workers in specific regions. This one will hit engineers, researchers and software companies, the parts of developed economies that were supposed to be insulated. A hospital comparing a Chinese-developed therapy against a Western one, or a logistics firm choosing between a European robot and a Chinese robot, is not making a political decision. It is reading a spreadsheet.
That is what makes “China shock 3.0” a useful if uncomfortable frame. It is not a prediction of collapse. It is a warning that the competitive ground has shifted from labor costs to technological capability, and that the countries and companies counting on a comfortable lead in AI, biotech and robotics may find that lead narrower than they assumed. The first two shocks took years to fully register. This one, powered by software that improves on its own schedule, may not offer the same grace period.